Wedbush Bullish on Nuvation Bio (NUVB) As NUVB Expands Safusidenib Rights

Wedbush Bullish on Nuvation Bio (NUVB) As NUVB Expands Safusidenib Rights Faheem Tahir Sun, April 12, 2026 at 5:54 PM EDT 2 min read NUVB 4568.T Nuvation Bio Inc. (NYSE: NUVB ) secures a spot on our list of the best penny stocks set to explode . Wedbush Bullish on Nuvation Bio (NUVB) As NUVB Expands Safusidenib Rights As of April 8, 2026, over 90% of covering analysts maintain their “Buy” ratings for Nuvation Bio Inc. (NYSE:NUVB), and the consensus price target of $12 implies an upside of 166.08%. On April 2, 2026, Wedbush maintained its “Buy” rating and $11 price target, providing a favorable backdrop as Nuvation Bio Inc. (NYSE:NUVB) expanded its strategic reach the day before. On April 1, 2026, Nuvation Bio Inc. (NYSE:NUVB) added Japan rights to its exclusive license deal with Daiichi Sankyo. This would grant the company the sole right to develop and market safusidenib worldwide. This development strengthens Nuvation Bio Inc. (NYSE:NUVB)’s capacity to support further publication and regulatory development in IDH1-mutant glioma by enabling the ongoing Phase 3 SIGMA study to extend into Japan and providing access to all current and future data. As a maintenance treatment for high-risk astrocytoma, safusidenib, an oral selective mutant IDH1 inhibitor, has demonstrated encouraging efficacy, including long-lasting responses and extended progression-free survival in Phase 1 and 2 trials. Nuvation Bio Inc. (NYSE:NUVB) is a biopharmaceutical company developing new treatments for di…